Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,798 total articles

SunScout Signs Definitive Agreement for First Philippine Solar-Plus-Storage Project, Expected to Add US$25 Million in Construction Revenue

SunScout Signs Definitive Agreement for First Philippine Solar-Plus-Storage Project, Expected to Add US$25 Million in Construction Revenue

SunScout Holding Limited has entered a definitive agreement to acquire the 25MW AKELCO solar-plus-storage project in the Philippines, anticipating $25 million in construction revenue and $1.2 million in average annual free cash flow over 20 years under a fixed-price power supply agreement. This marks the first project under a larger portfolio plan …

Exascale and EnergyBank Sign MOU to Develop AI Compute Powered by Full-Scale Floating Offshore Wind Turbine

Exascale and EnergyBank Sign MOU to Develop AI Compute Powered by Full-Scale Floating Offshore Wind Turbine

Exascale Labs Holdings Inc. (Nasdaq: XLAB) announced a non-binding MOU with EnergyBank to develop and potentially commercialize AI compute infrastructure powered by floating offshore wind turbines combined with long-duration energy storage. The initial pilot targets delivering up to 800kW of compute-ready power on an existing floating turbine, aimi…

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

AIM ImmunoTech announced that the US Patent and Trademark Office granted a patent covering the use of its drug Ampligen in combination with pembrolizumab (Keytruda) for cancer treatment. This patent, lasting until December 2039, supports Ampligen’s role in immuno-oncology, particularly focusing on pancreatic and other major cancers. The expanded pa…

Change Agents Completes Phase 2 of its Catch-Up Agentic AI Video Studio Platform; Development led by Caylent with Funding from Amazon Web Services Grant

Change Agents Completes Phase 2 of its Catch-Up Agentic AI Video Studio Platform; Development led by Caylent with Funding from Amazon Web Services Grant

Change Agents Corporation has completed Phase 2 development of its Catch-Up agentic AI video studio platform in collaboration with Caylent and with funding from an Amazon Web Services grant. The platform is designed to help digital content creators autonomously generate personalized short-form videos across multiple social media platforms. Beta tes…

OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company

OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company

OneMedNet Corporation announced a new agreement to provide its iRWD platform’s de-identified, full-fidelity clinical real-world data to a leading AI-driven drug development company, enabling rapid cohort feasibility, data validation, contracting, and delivery within weeks. This underscores the growing demand for private, directly sourced clinical d…

American Battery Technology Company Hosts DOE Leadership to Showcase Commercial Technologies Strengthening U.S. Critical Minerals Supply Chains

American Battery Technology Company Hosts DOE Leadership to Showcase Commercial Technologies Strengthening U.S. Critical Minerals Supply Chains

American Battery Technology Company hosted senior U.S. Department of Energy and Nevada state leaders at their commercial lithium-ion battery recycling facility and lithium hydroxide pilot plant. The visit highlighted the company's DOE-supported technologies that enhance domestic lithium resource development and recycling to reduce reliance on forei…

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Lexicon Pharmaceuticals announced results from a post hoc analysis of their Phase 3 SOLOIST-WHF trial, demonstrating sotagliflozin's consistent efficacy and safety across various baseline systolic blood pressure levels in patients recently hospitalized for worsening heart failure. The treatment reduced cardiovascular death and heart failure-related…

NeoVolta Announces Strategic U.S. Battery Cell Supply and BESS Manufacturing Collaboration with SK On

NeoVolta Announces Strategic U.S. Battery Cell Supply and BESS Manufacturing Collaboration with SK On

NeoVolta Inc. announced a strategic five-year agreement with SK On to secure 9 GWh of U.S.-manufactured lithium iron phosphate (LFP) battery cells from 2027 through 2031. Additionally, the companies will collaborate on an expanded framework where SK On supplies an additional 9 GWh of cells and NeoVolta manufactures energy storage packs for SK On, t…

Datacentrex Invests $30 Million in Eagle LNG Partners, a Supplier of Fuel for the U.S. Space Launch Industry

Datacentrex Invests $30 Million in Eagle LNG Partners, a Supplier of Fuel for the U.S. Space Launch Industry

Datacentrex, Inc. (Nasdaq: DTCX) announced a $30 million investment in Eagle LNG Partners via the equity holding company ELNG Equity LLC. Eagle LNG produces aerospace-specification liquefied natural gas (LNG) used to fuel next-generation American reusable launch vehicles and has established long-term contracts since 2017. The move positions Datacen…

Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline

Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline

Endovia Health Sciences welcomes the federal government's recent support for transferring marijuana from Schedule I to Schedule III, which marks a significant evolution in U.S. cannabinoid policy and is expected to facilitate scientific research and regulatory approval of cannabinoid-based medicines. The company plans to submit its CannEpil® formul…

IperionX Secures Second U.S. Army Task Order to Accelerate Industrial-Scale American Titanium Production

IperionX Secures Second U.S. Army Task Order to Accelerate Industrial-Scale American Titanium Production

IperionX Limited announces the U.S. Army awarded a second task order worth a base $18.5 million (with potential to reach $25.4 million) under its $99 million SBIR Phase III contract to scale industrial-scale, domestic titanium powder-to-part manufacturing capacity. This funding supports expanding titanium fastener finishing capabilities in Virginia…

Smackover Lithium Signs Binding Customer Offtake with LG Energy Solution for the South West Arkansas Project

Smackover Lithium Signs Binding Customer Offtake with LG Energy Solution for the South West Arkansas Project

Standard Lithium's Smackover Lithium partnership has executed a binding 10-year offtake agreement with LG Energy Solution for 8,000 metric tonnes per year of battery-quality lithium carbonate from the South West Arkansas Project. This deal complements a prior contract with Trafigura and secures approximately 90% of the expected output, strengthenin…

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

Supernus Pharmaceuticals announced a partnership with professional snowboarder Chloe Kim to raise awareness about adult ADHD and promote Qelbree, their non-stimulant ADHD medication. Qelbree, approved by the FDA five years ago, has become the top prescribed branded non-stimulant ADHD treatment with 3 million prescriptions. The collaboration aims to…